Drug intelligence / Profile preview

SPX-0152

Development stage: Preclinical
Lead developer: SpaceRx
Modality: Small Molecules
Administration: Oral

Overview

SPX-0152 is an oral, once-daily small molecule modulator of α4β2 nicotinic acetylcholine receptors (nAChRs) being developed by SpaceRx for smoking cessation and nicotine addiction. The drug targets the α4β2 nAChR subtype, which is the principal mediator of nicotine's reinforcing effects in the brain. SpaceRx employs a proprietary platform involving in-vivo real-time biosensors to evaluate and optimize prodrug candidates designed to provide sustained therapeutic levels and prolong therapeutic effects. The program has received National Institutes of Health (NIH) Small Business Innovation Research (SBIR) funding and is currently in the IND-enabling stage, with Phase 1 clinical trials expected to commence in 2026.

Targets

α4β2 nAChR (Nicotinic acetylcholine receptor alpha4 beta2 subtype)

Beyond the preview

Go deeper on SPX-0152.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SPX-0152.

Explore the full profile